Endo International plc reached a settlement agreement with Omeros Corp., agreeing not to launch a generic version of the Omidria eye drug before April 1, 2032.

Omeros sued the company after it filed an application seeking approval from the U.S. Food and Drug Administration to market a generic version of the medicine.

Omeros said the abbreviated new drug application infringed on its patents covering Omidria.

Endo acknowledged the validity of the patents and also agreed to pay a 15% royalty on the sales of its generic drug once it enters the market up until the last of the patents covering Omidria expires Oct. 23, 2033.